Health Technology Assessment

Under the newly-announced UK-US trade deal, the UK will increase the thresholds used to evaluate the cost-effectiveness of new medicines, which should allow higher prices for innovative therapies.

Rare disease drugs with limited evidence are most likely to be awarded a negative reimbursement recommendation in Denmark following a QALY-based health technology assessment, finds an analysis from industry group LIF.

Economic woes in France mean that tough and unpopular choices impacting the biopharmaceutical industry are inevitable, according to industry expert Alexandre Regniault.

The proportion of AMNOG benefit assessments leading to a positive rating, which has a direct impact on drug pricing, has decreased in recent years, according to analysis from the VFA, the association representing the German pharmaceutical industry.

In what seems to be the season of regulatory change in the UK, medtech stakeholders are checking their consultation diaries and gauging the value of the MHRA’s new AI Commission.

The Belgian Competition Authority has set out guidance on how pharmaceutical companies can share information on combination therapies when seeking their reimbursement.

The UK can look to other countries including Denmark, Spain and Canada for tips on how to make sure it is a competitive market for cell and gene therapies, according to the Cell and Gene Therapy Collective.

Health technology assessment authorities in Germany have concluded that CSL Behring’s Andembry offers significant additional benefits for hereditary angioedema patients, which could strengthen the company’s position during pricing negotiations.

IQWiG, Germany’s health technology assessment body, is making contingency plans in case key US resources it relies on for information retrieval, when conducting benefit assessments of new medicines, become unavailable.

IQWiG, Germany’s health technology assessment body, is making contingency plans in case key US resources it relies on for information retrieval, when conducting benefit assessments of new medicines, become unavailable.

Vertex and Biogen are working with the Dutch government to ensure access for eligible patients.

ZIN, the Dutch health technology assessment body, estimates that the number of patients eligible for treatment with a PARP inhibitor will be halved following a reassessment of drugs in the class.